Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Jodie Morrison |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 999 0232 |
| Website | q32bio.com |
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1661998 |
| CUSIP Number | 746964105 |
| ISIN Number | US7469641051 |
| Employer ID | 47-3468154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer and Director |
| Lee H. Kalowski M.B.A. | Chief Financial Officer and President |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer and President of Research |
| David Appugliese J.D. | Senior Vice President and Head of People |
| Maria Marzilli M.P.H. | Chief Business Officer |
| Dr. Adrien Sipos | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2026 | SCHEDULE 13D/A | Filing |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Feb 20, 2026 | SCHEDULE 13G | Filing |
| Feb 19, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 424B5 | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Dec 19, 2025 | 8-K | Current Report |